Literature DB >> 19881517

The management of patients awaiting liver transplantation.

Ka-Kit Li1, James Neuberger.   

Abstract

Since it was first performed in 1963, liver transplantation has become the only effective curative treatment in patients with liver failure. During the interval between being added to the waiting list and receiving a graft, the patient's condition may deteriorate as a result of disease progression or complications of the underlying liver disease. Both may result in death, removal from the waiting list because of futility of the procedure or, a worsened outcome following transplantation. The main aims during this period are to delay or prevent further deterioration in the patient's condition, to optimize their general medical health, to prevent, detect and treat any complications, and to offer treatment for specific conditions to improve the patient's overall outcome following liver transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19881517     DOI: 10.1038/nrgastro.2009.163

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  124 in total

Review 1.  Clinical practice: prevention of hepatitis B with the hepatitis B vaccine.

Authors:  Gregory A Poland; Robert M Jacobson
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

2.  Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.

Authors:  Satheesh Nair; Sumita Verma; Paul J Thuluvath
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

3.  Liver transplantation for hepatitis B in the United States.

Authors:  C Camci; A Gurakar; J Rose; S Rizvi; H Wright; T Bader; R Monlux; R R Schade; B M Nour; A Sebastian
Journal:  Transplant Proc       Date:  2005-12       Impact factor: 1.066

4.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

5.  Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

Authors:  Angelo Iacobellis; Massimo Siciliano; Francesco Perri; Brigida E Annicchiarico; Gioacchino Leandro; Nazario Caruso; Laura Accadia; Giuseppe Bombardieri; Angelo Andriulli
Journal:  J Hepatol       Date:  2006-10-20       Impact factor: 25.083

6.  Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

Authors:  Didier Samuel; Thierry Bizollon; Cyrille Feray; Bruno Roche; Si Nafa Si Ahmed; Catherine Lemonnier; Marielle Cohard; Michel Reynes; Michelle Chevallier; Christian Ducerf; Jacques Baulieux; Michael Geffner; Janice K Albrecht; Henri Bismuth; Christian Trepo
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

7.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

8.  Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis.

Authors:  S Hirsch; D Bunout; P de la Maza; H Iturriaga; M Petermann; G Icazar; V Gattas; G Ugarte
Journal:  JPEN J Parenter Enteral Nutr       Date:  1993 Mar-Apr       Impact factor: 4.016

9.  A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients.

Authors:  Deepali Kumar; Maggie Hong Chen; Gary Wong; Isabel Cobos; Brenda Welsh; Deborah Siegal; Atul Humar
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

10.  Impact of tips preliver transplantation for the outcome posttransplantation.

Authors:  G P Guerrini; M Pleguezuelo; S Maimone; V Calvaruso; E Xirouchakis; D Patch; N Rolando; B Davidson; K Rolles; A Burroughs
Journal:  Am J Transplant       Date:  2008-11-27       Impact factor: 8.086

View more
  4 in total

1.  Prognosis for recipients with hepatocellular carcinoma of salvage liver transplantation versus those of primary liver transplantation: a retrospective single-center study.

Authors:  Pusen Wang; Ying Pu; Hao Li; Baojie Shi; Shengnai Zheng; Lin Zhong
Journal:  Springerplus       Date:  2016-10-18

2.  Protective effect of eNOS overexpression against ischemia/reperfusion injury in small-for-size liver transplantation.

Authors:  Bo Zhang; Qiu-Hua Liu; Cui-Jie Zhou; Ming-Zheng Hu; Hai-Xin Qian
Journal:  Exp Ther Med       Date:  2016-09-30       Impact factor: 2.447

3.  Serial changes of serum growth factor levels and liver regeneration after partial hepatectomy in healthy humans.

Authors:  Kazuyuki Matsumoto; Yasuhiro Miyake; Yuzo Umeda; Hiroshi Matsushita; Hiroaki Matsuda; Akinobu Takaki; Hiroshi Sadamori; Kazuhiro Nouso; Takahito Yagi; Toshiyoshi Fujiwara; Kazuhide Yamamoto
Journal:  Int J Mol Sci       Date:  2013-10-17       Impact factor: 5.923

4.  Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series.

Authors:  Harrys A Torres; Ahmed Kaseb; Parag Mahale; Ethan Miller; Catherine Frenette
Journal:  J Hepatocell Carcinoma       Date:  2014-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.